Navigation Links
Lilly Reports Third-Quarter 2011 Results
Date:10/20/2011

als, Inc. and Alkermes, Inc., submitted a reply to a complete response letter issued in October 2010 by FDA regarding Bydureon™, an investigational medication for type 2 diabetes. The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) action date of January 28, 2012.
  • The company submitted its reply to a complete response letter by FDA regarding Amyvid™, a molecular Positron Emission Tomography (PET) imaging agent under investigation for the detection of beta-amyloid plaque in the brains of living patients.

  • The America Invents Act was signed into law, aligning new U.S. patent laws more closely with those from other countries and improving the global competiveness of U.S. innovator companies such as Lilly. The law will provide new advantages for U.S. inventors by streamlining the application process and addressing the backlog of current applications. This new law, which transitions the U.S. from a "first-to-invent" to a "first-inventor-to-file" system, is the most significant overhaul of the U.S. patent system in 175 years.

  • Third-Quarter Reported Results

    In the third quarter of 2011, worldwide total revenue was $6.148 billion, an increase of 9 percent compared with the third quarter of 2010. This 9 percent revenue growth was comprised of increases of 4 percent in volume and 4 percent due to the impact of foreign exchange rates. Price had a negligible impact on revenue growth, reflecting the loss of U.S. patent exclusivity for Gemzar® in November 2010. Total revenue in the U.S. increased 4 percent to $3.273 billion due to higher prices and increased volume. Total revenue outside the U.S. increased 15 percent to $2.874 billion due to the positive impact of foreign exchange rates and increased volume. Third-quarter 2011 total revenue was reduced by approximately $130 million due to the impact of U.S. health care reform.

    Gross margin increased 3.1 percent to $4.810 billion in the third quarte
    '/>"/>

    SOURCE Eli Lilly and Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. Lilly Declares Fourth-Quarter 2011 Dividend
    2. Lilly Announces Changes in Senior Management
    3. Lilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement
    4. Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
    5. Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference
    6. Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
    7. Lilly Health Channel Debuts on YouTube
    8. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
    9. The American Diabetes Association and Eli Lilly and Company Encourage African Americans to Learn About Diabetes Through a Familiar Face
    10. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
    11. U.S. Court of Appeals Affirms Validity of Lillys Strattera Patent
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)...  Lightbeam Health Solutions announced today an agreement ... ACO) to deploy the Lightbeam population health platform ... while reducing costs. Photo - ... Care Organization is the ACO operating entity of ... is to be the premier integrated health care ...
    (Date:9/17/2014)... Fla. , Sept. 17, 2014   myMatrixx, a pharmacy ... today that Business Insurance magazine has awarded ... distinction for the third year in a row. ... effort of Business Insurance  and the Best Companies ... is open to all publicly or privately-held insurance industry ...
    (Date:9/17/2014)... Sept. 17, 2014  NuView Life Sciences, Inc. ... and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. ... genomic-based diagnostic biomarker to detect cancers of the ... other future diagnostic-imaging applications. NuView retains all rights ... and in-vitro urine screen applications. Under ...
    Breaking Medicine Technology:Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3myMatrixx Honored with "Best Places to Work in Insurance" Award 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5
    ... 6 Reportlinker.com announces that a new ... catalogue. , Reportlinker Adds Gilead ... http://www.reportlinker.com/p0151769/Reportlinker-Adds-Gilead-Sciences-Inc-PharmaVitae-Profile.html , Introduction , This ... for Gilead in the prescription pharmaceutical sector. ...
    ... Oct. 6 Centocor Ortho Biotech Inc. and Schering-Plough ... European Commission has approved SIMPONI(TM) (golimumab) as a once-monthly, ... arthritis (RA), active and progressive psoriatic arthritis (PsA) and ... the European Union, SIMPONI is approved as a 50 ...
    Cached Medicine Technology:Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile 2Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile 3Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile 4SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 2SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 3SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 4SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 5SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 6SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 7SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 8SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 9SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 10
    (Date:9/17/2014)... North Central Surgical Center is proud to announce ... top-notch services. The hospital was the recipient for several ... , Hospital-wide, North Central was the recipient of the ... award for two years in a row (2013-2014). They ... nation for Patient Safety in 2014 and ranked among ...
    (Date:9/17/2014)... blood test that measures DNA from a prostate cancer ... the state of a man,s disease, a new study ... could reveal when treatment for advanced prostate cancer ... researchers suggested. "Our study showed that a steroid ... often initially very effective started to activate harmful mutations ...
    (Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
    (Date:9/17/2014)... Why are Asian Americans at higher risk of ... to develop the disease at lower body weights? One ... from traditional high-fiber, low-fat Asian diets to current westernized ... Asian heritage, says George King, M.D., Senior Vice President ... the senior author of the study. , A Joslin ...
    (Date:9/17/2014)... London, UK (PRWEB) September 17, 2014 ... of the total medical technology market, focusing on molecular ... cancer, chronic diseases, and genetic testing. The IVD market ... billion by the end of 2017. The major drivers ... testing; need for speed, which is evidenced by the ...
    Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
    ... explain the increased cases , FRIDAY, Nov. 6 (HealthDay News) ... people at higher risk of getting a type of thyroid ... related to cancer, but researchers suspect that the toxic compounds ... also unsure of why thyroid cancer rates are rising around ...
    ... a sneeze, people worry more about flu, heart attacks, accidents and ... may sound hard to believe, but just one sneeze is enough ... of dying from a heart attack at an early age, dying ... new research shows. , Of greater concern, however, was that people ...
    ... Nov. 6 HeartWare International, Inc. (Nasdaq: ... provider of less invasive, miniaturized circulatory support technologies revolutionizing ... it is scheduled to make presentations at two upcoming ... be made at the Third Annual Canaccord Adams Cardiovascular ...
    ... ... Award. , ... LA (PRWEB) November 6, 2009 -- Gilsbar, a national leader in health benefit ... was recently honored with Platinum-Level recognition for the American Heart Association Start! Fit-Friendly Companies ...
    ... ... and the recently released World Alzheimer Report declares that more than 35 million people ... innovator with 16 independent living and assisted living, and Alzheimer,s/memory care communities in Wisconsin ... of Alzheimer,s disease. , ...
    ... Tobacco-Free Kids, American Cancer Society, American Cancer Society Cancer ... American Legacy Foundation , WASHINGTON, Nov. 5 ... judge in Kentucky today rejected a motion by tobacco ... giving the U.S. Food and Drug Administration (FDA) the ...
    Cached Medicine News:Health News:Thyroid Cancer Higher in Volcanic Areas 2Health News:Health Fears Are Nothing to Sneeze At 2Health News:Health Fears Are Nothing to Sneeze At 3Health News:HeartWare to Present at Upcoming Investment Conferences in November 2Health News:Gilsbar is Sole Louisiana Company to Win National Award from the American Heart Association 2Health News:Top 10 Ways to Prevent or Delay Alzheimer's 2Health News:Federal Judge Rejects Tobacco Companies' Effort to Block Key Provisions of New Tobacco Regulation Law 2
    ... Single use curved circular ... and titanium staples., ,The ... stapler is used throughout the ... of end-to-end, end-to-side and side-to-side ...
    The Auto Suture™ EEA™ reusable stainless steel sizer set has application in intestinal, colorectal and esophageal surgery to help evaluate the diameter of tubular structures....
    ... is synthesized in the parafollicular C-cells of ... secretory granules. The major action of calcitonin ... inhibiting osteoclast activity, resulting in decreased mobilization ... is most evident in conditions associated with ...
    ... The pHEM-ALERT® test provides a method for ... The pHEM-ALERT test is comprised of a plastic ... color chart and a package insert. The plastic ... flat key. pHEM-ALERT is indicated for measuring vaginal ...
    Medicine Products: